CeNeRx BioPharma, a drug development company, engages in developing therapeutics to treat diseases related to the nervous system.
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 29, 2008 | Series B | $15M | 1 | — | — | Detail |
Nov 14, 2005 | Series A | $8M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Perseus-Soros Biopharmaceutical Fund | — | Series B |